TD Cowen analyst Tyler Van Buren has maintained their neutral stance on ARVN stock, giving a Hold rating on July 29.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tyler Van Buren has given his Hold rating due to a combination of factors affecting Arvinas Holding Company. The company’s recent NDA submission for vepdeg in 2L+ ESR1m BC patients is a significant step, but the supporting data is only modest, especially in a competitive market. The progression-free survival (PFS) data, while statistically significant, did not meet the previously identified threshold to stand out in the class.
Additionally, the collaboration with Pfizer is under review, as the cancellation of certain trials has led Arvinas to reconsider the terms of their agreement. The company is exploring other partnerships due to its lack of commercial infrastructure, which adds uncertainty to its future prospects. While the pipeline shows promise with upcoming Phase I data, these developments are still in early stages, contributing to the Hold rating.
In another report released on July 29, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $7.50 price target.